Jacoby Vanessa 4

What Happened Vanessa Jacoby, a director of Sonoma Pharmaceuticals, was granted an award of 10,000 derivative securities (options) on July 9, 2026. The filing lists the transaction as an award/acquisition (code A) with no per-share price reported (N/A). These are equity awards granted for her service on the Board and have not been exercised into common shares.

Key Details

• Transaction date: 2026-07-09; Form 4 filed 2026-07-09 (appears timely).
• Type: Award/Grant (derivative securities, code A); 10,000 options granted.
• Price/value: Not reported (N/A) in the filing.
• Vesting (footnote F1): Options vest one-third on each of 7/9/2027, 7/9/2028 and 7/9/2029, or fully upon a change of control.
• Purpose (footnote F2): Awarded for services performed on the Board of Directors.
• Shares owned after transaction: Not specified in the provided data.

Context This grant is a standard board compensation award (options) rather than an open-market purchase or sale, so it does not represent an immediate cash investment by the insider nor a realized sale. The options will convert to vested rights over three years (or accelerate on a change of control); they must be exercised according to plan terms before becoming shares. Such grants are common for directors and are primarily a retention/compensation tool rather than a direct signal of buying or selling.